Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387453 | 0.85 | — | — | |
| SCHEMBL10483535 | 0.85 | ALOX15 (0.44) | SIGMAR1ALDH1A1ALOX15KDM4ESMN1; SMN2 | |
| SCHEMBL1582630 | 0.84 | KDM1A (0.40) | MAPK1RAB9ASIGMAR1KDM1AALDH1A1 | |
| SCHEMBL294114 | 0.83 | DRD2 (0.43) | SIGMAR1ALOX15 | |
| SCHEMBL5391893 | 0.82 | GNAI3 (0.42) | MAPK1RAB9AKDM1AALDH1A1KDM4E | |
| SCHEMBL6661360 | 0.82 | KDM1A (0.45) | MAPK1RAB9ASIGMAR1CHRNA7KDM1A | |
| SCHEMBL6183476 | 0.82 | CARM1 (0.40) | SIGMAR1KDM4E | |
| SCHEMBL6183469 | 0.82 | GNAI3 (0.40) | MAPK1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5390210 | 0.80 | GNAI3 (0.45) | KDM1AALDH1A1KDM4E | |
| SCHEMBL5405364 | 0.80 | GNAI3 (0.45) | KDM1AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | claimed |
| EP-3298011-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-03-28 | — | — | EP | claimed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | claimed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | claimed |
| EP-2824108-B1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO LTD (CN) | 2017-04-19 | — | — | EP | claimed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | claimed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | claimed |
| EP-2824108-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2015-01-14 | — | — | EP | claimed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-22 | — | — | US | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | claimed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003080617-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| EP-1347972-A1 | PYRAZOLO 3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-01 | — | — | EP | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002050073-A1 | PYRAZOLO[3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPK1 1681/4885RAB9A 1439/4885SIGMAR1 4745/4885 |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | MAPK1 3301/4885RAB9A 674/4885SIGMAR1 3686/4885 |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | MAPK1 2079/4885RAB9A 461/4885SIGMAR1 4369/4885 |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | MAPK1 116/4885RAB9A 958/4885SIGMAR1 3788/4885 |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | MAPK1 334/4885RAB9A 2085/4885SIGMAR1 1419/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | MAPK1 3301/4885RAB9A 674/4885SIGMAR1 3686/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | MAPK1 702/4885RAB9A 2207/4885SIGMAR1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.